●第7回日本RNAi研究会、第2回細胞外小胞学会大会 ランチョンセミナーを行います。
| 演題 | ： | Exosomal microRNAs in urine ― promising biomarkers for prostate cancer 尿中エクソソーム由来マイクロRNAによる前立腺癌新規バイオマーカーの探索 |
| 演者 | ： | Michael Hansen, Ph.D. Technical Sales Specialist ― Senior Scientist Exiqon A/S【エキシコン社（デンマーク）】 |
| 開催日 | ： | 2015年8月27日（木） |
| 場所 | ： | グランドプリンスホテル広島 |
| MicroRNAs constitute a class of short RNAs which function as post-transcriptional regulators of gene expression. The expression patterns of microRNAs can accurately classify discrete tissue types and specific disease states which have positioned microRNAs as promising new biomarkers for diagnostic application in cancer. We have developed a highly sensitive LNA-based qPCR platform for microRNA detection, which enables profiling in biofluids where microRNA levels are extremely low. Thousands of biofluid samples including serum/plasma and urine have been profiled to determine normal reference ranges for circulating microRNAs as well as to identify biomarkers of disease. To develop a non-invasive diagnostic test for prostate cancer, we have combined our LNA-based qPCR with a recently developed exosome enrichment method, to identify diagnostic microRNAs in cell free urine from non-prostate-massaged men with early stages of prostate cancer. The preliminary data which we are currently validating in an independent cohort, indicate that a 2 microRNA signature facilitates separation of individuals with prostate cancer from normal individuals with a sensitivity and specificity of 89.2％ and 87.5％, respectively. We will discuss the importance of sample and data qualification which together with analysis method is crucial in securing high quality data from biofluids. |
